Sign in to fuzzto save your conversations, follow your research and come back anytime.
Alembic Pharmaceuticals
SectorHealthcare
Alembic Pharmaceuticals is an India-based company that manufactures and markets generic pharmaceutical products globally. It operates in India Formulations, International Generics, and Active Pharmaceutical Ingredients (API) segments. The company has state-of-the-art research and manufacturing facilities approved by regulatory authorities, including the US FDA. Alembic produces a range of generics across chronic segments, including Dermatology, Anti-Infective, Cardiology, and Anti-Diabetic therapies. The company has manufacturing facilities in Gujarat and Sikkim, with research and development centers in Vadodara, Hyderabad, and New Jersey. Alembic has expanded its operations through acquisitions, joint ventures, and international subsidiaries, focusing on developing and marketing generic drugs in various global markets.
The Quarter story
The two most recent quarterly results, compared side-by-side.
US pipeline accelerates with strong ANDA approvals and launches, while India branded sales hold firm in key categories despite rising input costs and margin pressure.
US Business Revenue grows from ₹5.64 Cr in Q4 FY26 to ₹7.78 Cr in Q1 2026-27, reflecting strong commercial execution.
Gross Margin compresses from 73% in Q2 FY26 to 71% in Q1 2026-27, signaling pricing or mix headwinds.
Consolidated ANDA Approvals rise from 4 in Q4 FY26 to 10 in Q1 2026-27, accelerating the US regulatory pipeline.
PAT Margin falls from 11% in Q4 FY26 to 8% in Q1 2026-27, indicating profit volatility despite revenue growth.
ISOFIT SR Market Share jumps from 14.5% in Q4 FY26 to 35.1% in Q1 2026-27, capturing significant category demand.
Material Consumption spikes from ₹5.32 Cr in Q4 FY26 to ₹6.20 Cr in Q1 2026-27, driven by higher production volumes.
ALTHROCIN Market Share recovers from 84.2% in Q4 FY26 to 87.8% in Q1 2026-27, retaining dominant market positioning.
India Branded Business Market Share slips from 1.3% in Q1 FY26 to 1.1% in Q1 2026-27, reflecting broader competitive pressure.
Total Income climbs from ₹18.73 Cr in Q4 FY26 to ₹21.65 Cr in Q1 2026-27, supporting overall top-line expansion.
BLADMIR Market Share drops from 8.8% in Q4 FY26 to 6.5% in Q1 2026-27, showing recent category weakness.
